1. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19:1167–214.
Article
2. Ahn HS, Kim HJ, Kim KH, et al. Thyroid cancer screening in South Korea increases detection of papillary cancers with no impact on other subtypes or thyroid cancer mortality. Thyroid. 2016; 26:1535–40.
Article
3. Cha YJ, Pyo JY, Hong S, et al. Thyroid fine-needle aspiration cytology practice in Korea. J Pathol Transl Med. 2017; 51:521–7.
Article
4. Powsner SM, Costa J, Homer RJ. Clinicians are from Mars and pathologists are from Venus. Arch Pathol Lab Med. 2000; 124:1040–6.
Article
5. Cibas ES, Ali SZ; NCI Thyroid FNA State of the Science Conference. The Bethesda System For Reporting Thyroid Cytopathology. Am J Clin Pathol. 2009; 132:658–65.
Article
6. Cibas ES, Ali SZ. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2017; 27:1341–6.
Article
7. Jung CK, Hong S, Bychkov A, Kakudo K. The use of fine-needle aspiration (FNA) cytology in patients with thyroid nodules in Asia: a brief overview of studies from the Working Group of Asian Thyroid FNA Cytology. J Pathol Transl Med. 2017; 51:571–8.
Article
8. Kang Y, Lee YJ, Jung J, Lee Y, Won NH, Chae YS. Morphometric analysis of thyroid follicular cells with atypia of undetermined significance. J Pathol Transl Med. 2016; 50:287–93.
Article
9. Yoo C, Choi HJ, Im S, et al. Fine needle aspiration cytology of thyroid follicular neoplasm: cytohistologic correlation and accuracy. Korean J Pathol. 2013; 47:61–6.
Article
10. Oosthuizen JL, Walker B, Todorovic E, Masoudi H, Wiseman SM. The presence of papillary features in thyroid nodules diagnosed as atypia of undetermined significance or follicular lesion of undetermined significance increases cancer risk and should influence treatment. Am J Surg. 2018; 215:819–23.
Article
11. Yashaswini R, Suresh TN, Sagayaraj A. Cytological evaluation of thyroid lesions by nuclear morphology and nuclear morphometry. J Cytol. 2017; 34:197–202.
Article
12. Vivero M, Renshaw AA, Krane JF. Adequacy criteria for thyroid FNA evaluated by ThinPrep slides only. Cancer Cytopathol. 2017; 125:534–43.
Article
13. Rossi M, Lupo S, Rossi R, et al. Proposal for a novel management of indeterminate thyroid nodules on the basis of cytopathological subclasses. Endocrine. 2017; 57:98–107.
Article
14. Satoh S, Yamashita H, Kakudo K. Thyroid cytology: The Japanese system and experience at Yamashita Thyroid Hospital. J Pathol Transl Med. 2017; 51:548–54.
Article
15. Kim SJ, Roh J, Baek JH, et al. Risk of malignancy according to subclassification of the atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS) category in the Bethesda system for reporting thyroid cytopathology. Cytopathology. 2017; 28:65–73.
Article
16. Misiakos EP, Margari N, Meristoudis C, et al. Cytopathologic diagnosis of fine needle aspiration biopsies of thyroid nodules. World J Clin Cases. 2016; 4:38–48.
Article
17. Kholová I, Ludvíková M. Thyroid atypia of undetermined significance or follicular lesion of undetermined significance: an indispensable Bethesda 2010 diagnostic category or waste garbage? Acta Cytol. 2014; 58:319–29.
Article
18. Shi Y, Ding X, Klein M, et al. Thyroid fine-needle aspiration with atypia of undetermined significance: a necessary or optional category? Cancer. 2009; 117:298–304.
19. Garg S, Naik LP, Kothari KS, Fernandes GC, Agnihotri MA, Gokhale JC. Evaluation of thyroid nodules classified as Bethesda category III on FNAC. J Cytol. 2017; 34:5–9.
Article
20. Rossi ED, Martini M, Capodimonti S, et al. Diagnostic and prognostic value of immunocytochemistry and BRAF mutation analysis on liquid-based biopsies of thyroid neoplasms suspicious for carcinoma. Eur J Endocrinol. 2013; 168:853–9.
Article
21. Fadda G, Rossi ED, Raffaelli M, et al. Follicular thyroid neoplasms can be classified as low- and high-risk according to HBME-1 and Galectin-3 expression on liquid-based fine-needle cytology. Eur J Endocrinol. 2011; 165:447–53.
Article
22. Ohori NP, Nikiforova MN, Schoedel KE, et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of “follicular lesion of undetermined significance/atypia of undetermined significance”. Cancer Cytopathol. 2010; 118:17–23.
Article
23. Cochand-Priollet B, Dahan H, Laloi-Michelin M, et al. Immunocytochemistry with cytokeratin 19 and anti-human mesothelial cell antibody (HBME1) increases the diagnostic accuracy of thyroid fineneedle aspirations: preliminary report of 150 liquid-based fine-needle aspirations with histological control. Thyroid. 2011; 21:1067–73.
Article
24. Abouhashem NS, Talaat SM. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics. Pathol Res Pract. 2017; 213:509–17.
Article
25. Solmaz OA. Diagnostic importance of CD56 with fine-needle aspiration cytology in suspected papillary thyroid carcinoma cases. Cytojournal. 2018; 15:3.
Article
26. Mokhtari M, Eftekhari M, Tahririan R. Absent CD56 expression in papillary thyroid carcinoma: A finding of potential diagnostic value in problematic cases of thyroid pathology. J Res Med Sci. 2013; 18:1046–50.
27. Nechifor-Boila A, Borda A, Sassolas G, et al. Immunohistochemical markers in the diagnosis of papillary thyroid carcinomas: the promising role of combined immunostaining using HBME-1 and CD56. Pathol Res Pract. 2013; 209:585–92.
Article
28. Nechifor-Boila˘ A, Ca˘tana˘ R, Loghin A, Radu TG, Borda A. Diagnostic value of HBME-1, CD56, galectin-3 and cytokeratin-19 in papillary thyroid carcinomas and thyroid tumors of uncertain malignant potential. Rom J Morphol Embryol. 2014; 55:49–56.
29. Scarpino S, Di Napoli A, Melotti F, Talerico C, Cancrini A, Ruco L. Papillary carcinoma of the thyroid: low expression of NCAM (CD56) is associated with downregulation of VEGF-D production by tumour cells. J Pathol. 2007; 212:411–9.
Article
30. Shahebrahimi K, Madani SH, Fazaeli AR, Khazaei S, Kanani M, Keshavarz A. Diagnostic value of CD56 and nm23 markers in papillary thyroid carcinoma. Indian J Pathol Microbiol. 2013; 56:2–5.
Article
31. Huang L, Wang X, Huang X, et al. Diagnostic significance of CK19, galectin-3, CD56, TPO and Ki67 expression and BRAF mutation in papillary thyroid carcinoma. Oncol Lett. 2018; 15:4269–77.
Article
32. Muzafar A, Bukhari MH, Qureshi IU. A study of galactin-3 on fine needle aspiration as a diagnostic marker differentiating benign from malignant thyroid neoplasm. Pak J Med Sci. 2017; 33:726–31.
Article
33. Golu I, Vlad MM, Dema A, et al. The absence of CD56 expression can differentiate papillary thyroid carcinoma from other thyroid lesions. Indian J Pathol Microbiol. 2017; 60:161–6.
Article
34. Abd El Atti RM, Shash LS. Potential diagnostic utility of CD56 and claudin-1 in papillary thyroid carcinoma and solitary follicular thyroid nodules. J Egypt Natl Canc Inst. 2012; 24:175–84.
Article
35. Ceyran AB, S¸enol S, S¸ims¸ek BÇ, Sag˘ırog˘lu J, Aydın A. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin. Int J Clin Exp Pathol. 2015; 8:3670–80.
36. Erdogan-Durmus S, Ozcan D, Yarikkaya E, Kurt A, Arslan A. CD56, HBME-1 and cytokeratin 19 expressions in papillary thyroid carcinoma and nodular thyroid lesions. J Res Med Sci. 2016; 21:49.
Article
37. Oh EJ, Hong SW, Jeong HJ, Yoon SO. The diagnostic approach to fine-needle aspiration of malignant lymphoma: using cytomorphology and immunocytochemistry with cell transfer method. Diagn Cytopathol. 2014; 42:671–9.
Article
38. Sherman ME, Jimenez-Joseph D, Gangi MD, Rojas-Corona RR. Immunostaining of small cytologic specimens: facilitation with cell transfer. Acta Cytol. 1994; 38:18–22.
39. Zu Y, Gangi MD, Yang GC. Ultrafast Papanicolaou stain and cell-transfer technique enhance cytologic diagnosis of Hodgkin lymphoma. Diagn Cytopathol. 2002; 27:308–11.
Article
40. El Demellawy D, Nasr AL, Babay S, Alowami S. Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid. Pathol Res Pract. 2009; 205:303–9.
Article
41. Zeromski J, Bagnasco M, Paolieri F, Dworacki G. Expression of CD56 (NKH-1) differentiation antigen in human thyroid epithelium. Clin Exp Immunol. 1992; 89:474–8.
Article
42. Ozolins A, Narbuts Z, Strumfa I, Volanska G, Stepanovs K, Gardovskis J. Immunohistochemical expression of HBME-1, E-cadherin, and CD56 in the differential diagnosis of thyroid nodules. Medicina (Kaunas). 2012; 48:507–14.
Article